A0,A0.35_Verb,A1,A2,Polarity,RelatedSentence
patients receiving,receive.01,the drug,,Affirmative,All - cause mortality was significantly reduced in patients receiving the drug in a pooled analysis with prior studies . 
"the ASCEND trial ,",turn.06,a survival benefit,,Affirmative,"SAN DIEGO -- The novel antifibrotic drug pirfenidone ( Esbriet ) slowed progression of idiopathic pulmonary fibrosis ( IPF ) in the ASCEND trial , which also turned up a survival benefit when pooled with prior pivotal trials . "
the ASCEND trial,show.01,an improvement in,,Affirmative,"While the trial did n't show an improvement in overall or disease - specific survival , a pooled analysis with the two prior pivotal trials ( CAPACITY trials ) did favor pirfenidone on both counts , they reported at the American Thoracic Society meeting and simultaneously online in the New England Journal of Medicine . "
pirfenidone,reduce.01,the risk of death,,Affirmative,"Across the pooled 1,247 patients , pirfenidone reduced the risk of death at 1 year by a relative 48 % overall and by 68 % for death from IPF ( P=0.01 and P=0.006 ) . "
The disease,have.03,a death rate worse than,,Affirmative,"The disease has a death rate worse than many cancers , with 3 - year survival of 50 % . "
Gary M. Hunninghake,say.01,", there has been little",,Affirmative,"But beyond providing information about prognosis or referral for lung transplantation or palliation , there has been little to offer in the way of treatment , he said . "
The new findings,offer.01,hope,,Affirmative,"The new findings offer hope that we may soon have choices in the medical management of idiopathic pulmonary fibrosis , he said . "
we,have.03,choices in,,Affirmative,"The new findings offer hope that we may soon have choices in the medical management of idiopathic pulmonary fibrosis , he said . "
Gary M. Hunninghake,say.01,findings offer hope,,Affirmative,"The new findings offer hope that we may soon have choices in the medical management of idiopathic pulmonary fibrosis , he said . "
"two prior multinational trials ,",show.01,only a small difference in,,Affirmative,"The trial was drugmaker InterMune 's response to the FDA 's 2010 refusal to approve pirfenidone in IPF on the basis of two prior multinational trials , which , combined , showed only a small difference in the surrogate endpoint and no differences in hard endpoints like exacerbations , lung transplantation , and mortality . "
the new results,tip.01,the balance,in favor of pirfenidone for,Affirmative,The question now is whether the new results will be enough to tip the balance in favor of pirfenidone for the FDA . 
we,do.02,they asked us,,Affirmative,"We did exactly what they asked us to do , and the results are even more positive than we expected , King told MedPage Today . "
they,ask.02,to do,us,Affirmative,"We did exactly what they asked us to do , and the results are even more positive than we expected , King told MedPage Today . "
King 's,think.01,FDA would look favorably on,,Affirmative,So I would think the FDA would look favorably on this compound . 
the FDA 's,look.01,on,,Affirmative,So I would think the FDA would look favorably on this compound . 
His group,argue.01,that they used,,Affirmative,"His group argued that they used reliable , valid , and responsive measures of disease status and independent predictors of the risk of death in IPF -- FVC and 6 - minute walk distance -- and found effects well above the estimated minimal clinically important difference for each . "
we,use.01,measures of,,Affirmative,"His group argued that they used reliable , valid , and responsive measures of disease status and independent predictors of the risk of death in IPF -- FVC and 6 - minute walk distance -- and found effects well above the estimated minimal clinically important difference for each . "
"editor-in-chief Jeffrey M. Drazen , MD ,",have.03,high praise for,,Affirmative,"NEJM editor-in-chief Jeffrey M. Drazen , MD , had high praise for the study overall , calling the results really good news and groundbreaking . "
"editor-in-chief Jeffrey M. Drazen , MD ,",call.01,the new results,good news and groundbreaking,Affirmative,"NEJM editor-in-chief Jeffrey M. Drazen , MD , had high praise for the study overall , calling the results really good news and groundbreaking . "
Jeffrey M. Drazen,urge.01,the researchers,not to rest upon,Affirmative,"However , he urged researchers not to rest upon just slowing the disease . "
the researchers,rest.01,upon,,Affirmative,"However , he urged researchers not to rest upon just slowing the disease . "
the researchers,slow.01,The disease,,Affirmative,"However , he urged researchers not to rest upon just slowing the disease . "
you,have.03,a significant impact,,Affirmative,"It 's great , you 're having a significant impact , you 're halving the death rate over this time , he said . "
you,halve.01,the death rate,,Affirmative,"It 's great , you 're having a significant impact , you 're halving the death rate over this time , he said . "
Jeffrey M. Drazen,say.01,It 's great,,Affirmative,"It 's great , you 're having a significant impact , you 're halving the death rate over this time , he said . "
these people,have.03,a death sentence,,Affirmative,"But these people have a death sentence , they just have longer . "
these people,have.03,longer,,Affirmative,"But these people have a death sentence , they just have longer . "
The disease,do.02,these people,,Affirmative,They get to live with their disease longer before it does them in . 
That ASCEND,randomize.01,555 patients,with,Affirmative,"ASCEND randomized 555 patients with centrally - confirmed IPF to receive either oral pirfenidone ( a total of 2,403 mg divided into three doses daily ) or placebo for 1 year . "
the primary endpoint,seek.01,a slowing in,,Affirmative,"While the primary endpoint sought a slowing in the progressive loss of lung function seen from fibrotic scarring , pirfenidone substantially increased the proportion of patients with no decline in FVC ( 22.7 % versus 9.7 % , P < 0.001 ) . "
pirfenidone,increase.01,the proportion of patients,with,Affirmative,"While the primary endpoint sought a slowing in the progressive loss of lung function seen from fibrotic scarring , pirfenidone substantially increased the proportion of patients with no decline in FVC ( 22.7 % versus 9.7 % , P < 0.001 ) . "
Pirfenidone,reduce.01,the decline in,,Affirmative,"Pirfenidone reduced the decline in the 6 - minute walk distance at week 52 , with 25.9 % of patients losing 50 m or more or dying compared with 35.7 % ( P=0.04 ) . "
"free survival , defined as alive",predict.01,m loss,,Affirmative,"Overall progression - free survival , defined as alive without a 10 percentage point decrease in percent predicted FVC or 50 m loss in 6 - minute walk distance , also improved with the drug compared with placebo ( hazard ratio 0.57 , 95 % CI 0.43-0.77 ) . "
the drug in a pooled analysis with prior studies,improve.01,dyspnea scores ( P=0.16 ),,Affirmative,"However , the drug did n't improve dyspnea scores ( P=0.16 ) or rates of death from any cause ( 4.0 % versus 7.2 % , P=0.10 ) or from IPF ( 1.1 % versus 2.5 % , P=0.23 ) . "
common serious adverse event,worsen.01,IPF,,Affirmative,The most common serious adverse event was worsening IPF . 
group,note.01,these were still in,,Affirmative,"Clinically significant elevations in aminotransferase levels occurred more with pirfenidone but King 's group noted these were still in less than 3 % of patients , were reversible , and did not have clinically significant consequences . "
That ASCEND,succeed.01,may have been because of,,Affirmative,"That ASCEND succeeded where the CAPACITY 006 pivotal trial failed may have been because of the higher placebo response in CAPACITY , they noted . "
patients who fall outside the recruitment criteria for these trials,note.01,ASCEND succeeded,,Affirmative,"That ASCEND succeeded where the CAPACITY 006 pivotal trial failed may have been because of the higher placebo response in CAPACITY , they noted . "
our,modify.01,certain aspects of,,Affirmative,"In our study , we modified certain aspects of the CAPACITY study design , including increasing the sample size and requiring central confirmation of the diagnosis , they explained . "
they,explain.01,", we modified",,Affirmative,"In our study , we modified certain aspects of the CAPACITY study design , including increasing the sample size and requiring central confirmation of the diagnosis , they explained . "
our,modify.01,selected eligibility criteria,,Affirmative,We also modified selected eligibility criteria in order to enroll patients at higher risk for disease progression . 
our,say.01,militates against,,Affirmative,"Still , there was general similarity in 1 year results compared with the pivotal trials studies without central diagnosis confirmation , which they said militates against any limitation that this requirement might impose on the generalizability of our results . "
this requirement,impose.01,any limitation,on,Affirmative,"Still , there was general similarity in 1 year results compared with the pivotal trials studies without central diagnosis confirmation , which they said militates against any limitation that this requirement might impose on the generalizability of our results . "
The study population,mild.01,moderate physiological impairment,,Affirmative,"The study population had mild - to - moderate physiological impairment , so it 's not clear how well the results would generalize to patients with advanced disease , the group cautioned . "
the new results,generalize.01,to patients with,,Affirmative,"The study population had mild - to - moderate physiological impairment , so it 's not clear how well the results would generalize to patients with advanced disease , the group cautioned . "
patients with advanced disease,extrapolate.01,The new findings,to patients,Affirmative,"Although these results are a major breakthrough for patients with idiopathic pulmonary fibrosis , we should be cautious in extrapolating these findings to patients who fall outside the recruitment criteria for these trials , Hunninghake added , in referencing the group of trials reported together here . "
Gary M. Hunninghake,reference.01,the group of trials,,Affirmative,"Although these results are a major breakthrough for patients with idiopathic pulmonary fibrosis , we should be cautious in extrapolating these findings to patients who fall outside the recruitment criteria for these trials , Hunninghake added , in referencing the group of trials reported together here . "
by InterMune,fund.01,the ASCEND trial,,Affirmative,The trial was funded by InterMune . 
King 's,disclose.01,"relationships with InterMune ,",,Affirmative,"King disclosed relationships with InterMune , Immune Works , Daiichi Sankyo , Boehringer Ingelheim , and the NIH . "
Gary M. Hunninghake,disclose.01,no relevant relationships with industry,,Affirmative,Hunninghake disclosed no relevant relationships with industry . 
those,choose.01,to participate,,Affirmative,"This survey is a poll of those who choose to participate and are , therefore , not valid statistical samples , but rather a snapshot of what your colleagues are thinking . "
by,power.01,"MedPageToday , powered by",,Affirmative,"MedPageToday , powered by Everyday Health Inc . "
coverage,affect.01,the lives and practices of,,Affirmative,", is a trusted and reliable source for clinical and policy coverage that directly affects the lives and practices of health care professionals . "
Physicians and,receive.01,Continuing Medical Education ( CME ) and,,Affirmative,Physicians and other healthcare professionals may also receive Continuing Medical Education ( CME ) and Continuing Education ( CE ) credits at no cost for participating in MedPage Today - hosted educational activities . 
Use of,constitute.01,acceptance of,,Affirmative,Use of this site constitutes acceptance of the MedPageToday.com terms of use and privacy policy . 
by,provided.01,"medical advice ,",,Affirmative,"The material on this site is for informational purposes only , and is not a substitute for medical advice , diagnosis or treatment provided by a qualified health care provider . "
